Your essential biotech, medtech, and pharma recap — no noise, just what matters.

The FDA's real-time clinical trial announcement is the most structurally significant regulatory initiative since the Expedited IND proposal in March. For 60 years, clinical trial data has followed the same path: collected at sites, sent to sponsors, analyzed, then submitted to the FDA in batches. Under the RTCT framework, the FDA receives aggregated safety and efficacy signals in the cloud as they occur. No raw patient data. No identifying information. Just rates of adverse events, tumor response percentages, and other endpoints flowing directly to regulators in real time. AstraZeneca's Phase 2 TRAVERSE trial in mantle cell lymphoma is already transmitting data through Paradigm Health's platform. Amgen's Phase 1b STREAM-SCLC trial in small cell lung cancer is in final site selection. Commissioner Makary said nearly half of the 10-to-12-year development timeline passes "with no trial actually running." This initiative aims to compress that dead time. Meanwhile, Novartis reported what the patent cliff actually looks like: Entresto, which was 14% of total sales last year, dropped 42% in a single quarter. The company expects $4B in sales erosion this year. And Lilly, apparently unstoppable, signed its sixth deal of 2026, a $2.25B AI gene editing collaboration with Profluent Bio that Profluent's CEO called an attempt to unlock the "holy grail" of genetic medicine. 👉 Read Full Analysis

The FDA Launches Real-Time Clinical Trial Data Monitoring

What Happened: The FDA announced on April 28 two major steps toward implementing real-time clinical trials (RTCT). First, two proof-of-concept trials are already operational. Second, the agency released a Request for Information on a broader pilot program that will launch this summer.

The Pilots:

AstraZeneca TRAVERSE (Phase 2): Testing acalabrutinib combination therapy in treatment-naive mantle cell lymphoma. Sites include MD Anderson Cancer Center and University of Pennsylvania. The FDA has already received and validated safety data signals through Paradigm Health's platform, establishing the technical feasibility of real-time signal sharing.

Amgen STREAM-SCLC (Phase 1b): Testing an undisclosed treatment in limited-stage small cell lung carcinoma. Final site selection is in process.

How It Works: FDA Chief AI Officer Jeremy Walsh said the agency is not seeking access to raw patient records. Instead, sponsors transmit only aggregated signals (adverse event rates, response percentages, endpoint data) via a cloud-based platform operated by Paradigm Health. Individual patient records remain with the trial sponsor. This avoids patient privacy concerns while giving the FDA visibility into trial progress as it happens.

Executive Impact: Commissioner Makary said: "We're announcing a bold new approach that could fundamentally transform this clinical trial landscape." He noted that the typical 10 to 12 year development timeline includes nearly half the time where no trial is actually running. By monitoring data in real time, the FDA can potentially shorten the interval between trial phases, make faster go/no-go decisions, and identify safety signals earlier. AstraZeneca oncology SVP Amy McKee called it a step toward moving "data as quickly as possible across this ecosystem." The RFI solicits public comment through May 29 on expanding RTCT to a formal pilot. For biotechs, CDMOs, and CROs, this could fundamentally change how trials are designed, monitored, and reported.

👉 Read Full Analysis

The real-time clinical trial framework has three levels of impact:

For pharma sponsors: Faster FDA feedback loops mean shorter intervals between trial phases. If the FDA can see safety signals in real time, Phase 1 to Phase 2 transitions could be compressed from months to weeks. That directly reduces development cost and time-to-market. AstraZeneca and Amgen signed on first, but every major sponsor will evaluate participation once the pilot program opens this summer.

For CROs and CDMOs: Real-time data transmission requires new infrastructure. The Paradigm Health platform is the first to be validated by the FDA for this purpose. CROs that integrate real-time signal reporting into their offerings will have a competitive advantage. Those that do not adapt risk losing business to technology-first competitors.

For medtech and digital health: The RFI does not limit RTCT to pharmaceutical trials. Device trials, digital therapeutics studies, and surgical outcomes registries could all eventually adopt real-time signal sharing. For medtech companies running large-scale trials (Medtronic, Boston Scientific, Abbott), this could accelerate 510(k) and PMA submissions.

The limiting factor is standardization. Real-time signal sharing requires agreed-upon data formats, aggregation methods, and signal definitions. The RFI is the FDA's way of soliciting industry input on those standards before formalizing the program.

Novartis's Q1 results are a case study in patent cliff management. Entresto fell 42% in one quarter. That is $960M in annualized revenue lost to generics. The total expected erosion this year is $4B across three drugs.

What Novartis did right: build a portfolio of high-growth assets (Kisqali, Pluvicto, Kesimpta, Scemblix, Leqvio) that collectively grew faster than any other major pharma's pipeline brands in Q1. The problem: the growth brands generated roughly $8B in combined Q1 sales while the legacy erosion subtracted enough to push total revenue below expectations.

The math is simple. Novartis needs to generate approximately $4B in incremental growth-brand revenue to offset the patent cliff. That requires the five priority brands to grow at a combined ~50% rate, which they approximately delivered in Q1. The question is sustainability. Can Kisqali and Pluvicto maintain 55-70% growth through H2 with increasing competition (Verzenio for Kisqali, PSMAfore for Pluvicto)?

For every pharma executive watching: Novartis is the preview. Merck (Keytruda, 2028), AbbVie (Humira, ongoing), and BMS (Eliquis/Revlimid, ongoing) are all navigating their own cliffs. The playbook is the same: build new brands fast enough to outrun the decline.

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →